Editas Medicine Stock News

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wedn

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednes

They point to trouble for investors counting on a rebound.

They point to trouble for investors counting on a rebound.

James C. Mullen to Serve as Executive Chairman

The only thing standing in the way is the clinical trials process, which takes time and patience.

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Plus Tess Vigeland, host of The Wall Street Journal podcast "As We Work," joins us for a chat.

Editas has two CRISPR genome editing techniques which are CRISPR/Cas9 and CRISPR/Cas12a.

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024 WALTHAM, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ: TCRX ), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities. "As we had guided throughout 2021, in December we filed two INDs for our liquid tumor program. We also completed construction of our now fully functional 7,000 square-foot GMP manufacturing facility. Both of these steps are instrumental in our transformation to a clinical-stage company," said David Southwell, President and Chief Executive Officer. "We also advanced our growing pipeline of solid tumor candidates and look forward to sharing further details around these programs in the coming months." Recent Corporate Highlights In January 2022, the Company announced that the U.S.